COOPERSTOWN, N.Y. — Bassett Healthcare Network has been selected as a clinical-trial site for Alpha DaRT, an investigational treatment for recurrent skin cancers. Bassett Cancer Institute received regulatory approval to conduct the trial. “We are proud to be chosen as the first clinical-trial site for Alpha DaRT statewide outside of New York City,” Dr. Timothy […]
Get Instant Access to This Article
Become a Central New York Business Journal subscriber and get immediate access to all of our subscriber-only content and much more.
- Critical Central New York business news and analysis updated daily.
- Immediate access to all subscriber-only content on our website.
- Get a year's worth of the Print Edition of The Central New York Business Journal.
- Special Feature Publications such as the Book of Lists and Revitalize Greater Binghamton, Mohawk Valley, and Syracuse Magazines
Click here to purchase a paywall bypass link for this article.
COOPERSTOWN, N.Y. — Bassett Healthcare Network has been selected as a clinical-trial site for Alpha DaRT, an investigational treatment for recurrent skin cancers.
Bassett Cancer Institute received regulatory approval to conduct the trial.
“We are proud to be chosen as the first clinical-trial site for Alpha DaRT statewide outside of New York City,” Dr. Timothy Korytko, Bassett Healthcare Network chief radiation oncologist, said in a news release. “Bassett Cancer Institute’s full team of nationally accredited medical, radiation, and surgical oncologists, as well as oncology-certified registered nurses, provide the highest standard of care to our patients in Central New York state and beyond.”
Alpha DaRT delivers a highly potent radiation treatment for solid cancer tumors. This differs from local radiation therapy, a mainstay of cancer therapy, which is most limited to modalities using beta or gamma emissions. Alpha DaRT uses alpha particles directly inserted into solid cancer tumors, providing an option to kill cancerous cells without damaging surrounding health tissue.
“Bassett is constantly evolving to meet the changing needs of the people and the region we serve,” Bassett President/CEO Dr. Tommy Ibrahim said. “Bringing advanced care to our rural communities is central to our mission. We are honored to join an esteemed group of healthcare institutions nationwide as a clinical-trial site for a promising treatment option.”
Bassett recently began offering radiopharmaceutical treatments with Lutathera, a radiation therapy for neuroendocrine cancer, and Pluvicto, a treatment for metastatic prostate cancer.
Bassett Healthcare Network operates five hospitals, more than two dozen community-based health centers, 21 school-based health centers, and two skilled-nursing facilities to serve a 5,600-square-mile region of upstate New York.